Companies Dominating the Anti-HA Antibody Landscape
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson
- Merck KGaA
- Novartis International AG
- AbbVie Inc.
- Amgen Inc.
- Pfizer Inc.
- Bayer AG
- Eli Lilly and Company
- Bristol-Myers Squibb Company
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of anti-HA antibody is assessed at USD 1.14 billion.
The anti-HA antibody market size was over USD 1.07 billion in 2024 and is projected to reach USD 2.64 billion by 2037, witnessing around 7.2% CAGR during the forecast period i.e., between 2025-2037. Increasing cases of influenza flu in people worldwide will fuel the market growth.
North America industry is expected to account for largest revenue share of 36% by 2037, owing to increasing cases of influenza flu in the region.
The major players in the market are F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck KGaA, Novartis International AG, AbbVie Inc., Amgen Inc., Pfizer Inc., Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Co Ltd, Takeda Pharmaceutical Co Ltd., Chugai Pharmaceutical Co Ltd, Sanofi KK.
